StockData

Gyre Therapeutics vs Zevra Therapeutics

GYRE and ZVRA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GYRE and ZVRA compare

Gyre Therapeutics and Zevra Therapeutics are about the same size, with market caps of $508M and $558M.

Zevra Therapeutics grew revenue faster over the last twelve months (119% versus −3.7% for Gyre Therapeutics).

Zevra Therapeutics keeps more of each dollar of sales as profit, with a net margin of 42.8% compared with −33.9% at Gyre Therapeutics.

Zevra Therapeutics scores higher on the StockData Score (15 against 11 for Gyre Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGYREZVRA
Size and price
Market cap$508M$558M
Share price$4.56$9.40
Change, 1 year−42.9%5.9%
Change, 5 years−75.7%16.8%
Beta (5Y)1.211.16
Employees61861
StockData Score
Total score1115 (better)
Valuation score13 (better)
Growth score13 (better)
Performance score33
Health score66
Dividend score00
Valuation
P/E–10.1×
P/S4.7×4.1× (better)
P/B4.7×2.6× (better)
EV/EBITDA–4.0×
P/FCF–17.1×
FCF yield−1.5%5.8% (better)
Fair value$5.29$23.57
Margin of safety13.8%60.1% (better)
Growth
Revenue growth (TTM)−3.7%119% (better)
Revenue growth, 5Y average41.0%51.6% (better)
Net income growth (TTM)−801%2104% (better)
Profitability
Gross margin93.4%95.5% (better)
Operating margin−14.4%60.5% (better)
Net margin−33.9%42.8% (better)
FCF margin−7.2%24.0% (better)
Return on equity−34.9%34.8% (better)
Return on invested capital−26.6%–
Financial health
Debt / equity0.000.00
Net debt / EBITDA–−2.64
Interest coverage–14.4×
Current ratio4.325.17 (better)
Altman Z-score8.53 (better)4.35
Piotroski F-score56 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions7.8%78.5%
Held by insiders93.8%1.2%
Insider net buying, 12 months−$953K (better)−$2.5M
Short interest, % of float32.4%11.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.